MPLT:NASDAQMapLight Therapeutics, Inc. analysis
Data as of Oct 14, 2026 - not real-time
- Latest price
- $7.79
- Risk: high
- 9/10High risk
Summary
At $7.79, MapLight Therapeutics, Inc. shows a bearish moving-average alignment, with shorter averages beneath longer ones. Over a rolling month the price has lost 41.5%. RSI sits at 21.1, which reads as oversold, and MACD momentum is bearish. Recent trading has carved out support near $7.60 and resistance around $11.73.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 240.9% above today's level.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 51.9%, a beta of 0.85 and a maximum drawdown of 80.4%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
All three time horizons resolve to hold, carrying 1/10 conviction.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 240.9% above today's level.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 51.9%, a beta of 0.85 and a maximum drawdown of 80.4%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
All three time horizons resolve to hold, carrying 1/10 conviction.
Top market events
- SAN FRANCISCO and BOSTON, June 24, 2026 GLOBE NEWSWIRE -- MapLight Therapeutics, Inc.
- SAN FRANCISCO and BOSTON, Sept. 09, 2026 GLOBE NEWSWIRE -- MapLight Therapeutics, Inc. Nasdaq: MPLT today announced...
- SAN FRANCISCO and BOSTON, Sept. 09, 2026 GLOBE NEWSWIRE -- MapLight Therapeutics, Inc. Nasdaq: MPLT today announced...
Market outlook
Short term
< 1 yearNeutral
Model confidence3/103 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- RSI at 21.1 signals oversold conditions
- Trading below the 200-day average of 21.09
Medium term
1–3 yearsNeutral
Model confidence2/102 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- RSI at 21.1 signals oversold conditions
- Trading below the 200-day average of 21.09
Long term
> 3 yearsNeutral
Model confidence1/101 out of 10
Key factors
- Analyst targets imply +240.9% versus the current price
- Negative return on equity of -111.5%
- Negative free cash flow
Key metrics
Financial health
P/E Ratio-2.3
ROE-111.55%
ROA-67.11%
Debt/Equity0.57
P/B Ratio1.0
Op. Cash Flow$-174668000
Free Cash Flow$-95213000
Industry P/E30.7
Technical analysis
TrendBearish
RSI21.1
Support$7.60
Resistance$11.73
MA 20$9.84
MA 50$11.42
MA 200$21.09
MACDBearish
VolumeDecreasing
Fear & Greed Index93.3
Valuation
Target Price$26.54
Upside/Downside240.89%
GradeFair
TypeBlend
Risk assessment
Beta0.85
Volatility51.94%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.